Clinical Trials Browser

Observational × Nivolumab × 1 year × Clear all

NCT07419932 2026-02-19

NeoLATC

Thyroid Neoplasms

NCT07394062 2026-02-06

ALCG-01

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06599619 2026-01-26

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

Dysplastic Nevus Syndrome, Melanoma, Hereditary Sensory and Autonomic Neuropathies

NCT07141563 2026-01-07

A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

Carcinoma, Non-Small-Cell Lung

NCT06452329 2025-12-04

A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

Gastrointestinal

Stomach Neoplasms

NCT05287464 2025-11-26

International Multicentric Study ARON-1

Carcinoma, Renal Cell

NCT07223411 2025-11-26

Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

Locally Advanced Melanoma

NCT07091695 2025-11-12

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

Melanoma

NCT06345183 2025-11-06

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Advanced Renal Cell Carcinoma (aRCC)

NCT03963518 2025-10-06

SURROGATE-ICI

631 enrolled 6 charts

Neoplasms

NCT06771674 2025-09-09

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT07092670 2025-09-05

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

Melanoma, Skin Neoplasms

NCT07098104 2025-08-01

A Benefit Population Atlas of nICT Versus nCT for LAGC

Gastrointestinal

Stomach Neoplasms

NCT04050761 2025-07-02

ProNiHN

Head and Neck Neoplasms

NCT07024862 2025-06-17

Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06421311 2025-06-05

URADJ

Carcinoma, Transitional Cell

NCT06499298 2025-05-31

Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer

Gastrointestinal

Esophageal Neoplasms

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung